Flomax Articles
Outlook for generic equivalent of Pfizer’s Lipitor; how will US exclusivity resolve? asks law firm HPM
14 October 2010
Takeda files NDA for azilsartan medoxomil in USA, settles Actos patent disputes; Actavis debuts generic Flomax
29 April 2010
Ranbaxy back in black in fourth quarter as US sales soar
26 February 2010
Japanese drug major Astellas’ 3rd quarter net profit slumps 47% as Prograf hit by generic competition
3 February 2010
UK regulatory agency clears prostate drug Flomax for OTC use; generic competition due next year in USA
14 December 2009
Boehringer Ingelheim launches co-pay rebate program for Viramune in USA; settles with Impax over Flomax
7 October 2009
Japan stock market week to May 18, 2009
19 May 2009
Boehringer's 2008 net sales jump 6.4%
24 April 2009
Warning on ED drug-drug interactions
19 January 2009
Astellas looking to overtake Takeda's leading share of home market with newer products
15 September 2008
Boehringer's first-half 2008 profit drops 10%
18 August 2008
Boehringer's first-half 2008 profit drops 10%
18 August 2008
FDA approval for GSK's Avodart
30 June 2008
Spiriva and Micardis boost Boehringer's 2007 sales 8.8%, as profit jumps 4.8% to $2.8M
14 April 2008
GSK's combo drug "to be BPH gold standard by 2011"
3 March 2008
Tokyo stocks to February 11, 2008
18 February 2008
Tentative OK for Teva's generic Flomax
11 February 2008
Astellas/Boeh Ing settle with Ranbaxy over Flomax
12 November 2007
Bentley's Spanish units get approval for tamulosin
2 April 2007
Japan stock market week to March 5, 2007
12 March 2007
Astellas' fiscal 06/07 first-half net sales rise 5%
20 November 2006
Astellas sees solid fiscal 1st-qtr 2006
20 February 2006
FDA warns against foreign Rx drugs
16 January 2006
Astellas launches Flomaxtra XL in UK
5 September 2005
Good 1st-qtr results for Shionogi
22 August 2005
BI's Flomax shows good AE profile
18 July 2005
Japan stock market week to January 17
24 January 2005
BI 1st-half sales up 7%
23 August 2004
Tokyo pharma stocks - week to August 16
23 August 2004
Abbott reports sharp rise in 4-qtr profit
26 January 2004
Abbott earnings up as core sales grow
20 October 2003
Abbott earnings up as core sales grow
20 October 2003
BI hit by costs and currencies in first half
11 August 2003
Errata: Flomox/Flomax
16 June 2003
Cost-cutting reaps dividends at Shionogi
2 June 2003
Abbott's profits up 2%, forecasts lowered
27 January 2003
Boehringer Ingelheim's operating income up 48% in first half; Spiriva prospects strong
19 August 2002
Tokyo pharma stocks - week to January 21
28 January 2002
Abbott posts strong revenue growth for 2001, but charges hit
21 January 2002
Stock Commentary - Tokyo
18 October 2001
Japan pharma stock market - week to October 15
17 October 2001
Abbott sales up 26% though earnings slip
11 October 2001
Abbott sales up 26% though earnings slip
10 October 2001
Solid first-half 2001 for Boeh Ingelheim
29 August 2001
Abbott sales growth driven by pharma
13 July 2001
US pharma business driving Abbott
17 April 2001
US pharma business driving Abbott
12 April 2001
BI and Abbott to copromote Flomax in USA
19 August 1999
BI and Abbott to copromote Flomax in USA
19 August 1999
GW to co-promote Flomax MR in UK
17 February 1999
Yamanouchi's Flomax Launched In USA
16 October 1997
UK Industry Code Of Practice Report
1 September 1997
Flomax Approved In The USA
12 May 1997
UK Industry Code Of Practice In 1996
24 March 1997
Tamsulosin Launches
24 June 1996
Showing 1-71 of 71 articles
- 1
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
